The Efficacy and Toxicity of Gefitinib in Treating Non-small Cell Lung Cancer: A Meta-analysis of 19 Randomized Clinical Trials

Wo, Hongmei; He, Jing; Zhao, Yang; Yu, Hao; Chen, Feng; Yi, Honggang

doi:10.7150/jca.23356

International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

open access Global reach, higher impact

Full Text | PDF

J Cancer 2018; 9(8):1455-1465. doi:10.7150/jca.23356 This issue Cite

Research Paper

The Efficacy and Toxicity of Gefitinib in Treating Non-small Cell Lung Cancer: A Meta-analysis of 19 Randomized Clinical Trials

Hongmei Wo¹, Jing He², Yang Zhao², Hao Yu², Feng Chen^2✉, Honggang Yi^2✉

1. Department of Health Economics, School of Health Policy and Management, Nanjing Medical University, Nanjing, 211166, China
2. Department of Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, 211166, China

Citation:

Wo H, He J, Zhao Y, Yu H, Chen F, Yi H. The Efficacy and Toxicity of Gefitinib in Treating Non-small Cell Lung Cancer: A Meta-analysis of 19 Randomized Clinical Trials. J Cancer 2018; 9(8):1455-1465. doi:10.7150/jca.23356. https://www.jcancer.org/v09p1455.htm

Other styles

Abstract

Background: This meta-analysis evaluated the efficacy and toxicity of gefitinib with other commonly used drugs in different treatment settings and epidermal growth factor receptor (EGFR) mutation status.

Methods: Nineteen randomize clinical trials (RCTs) of 6,554 patients with NSCLC were pooled in this meta-analysis by random-effects or fixed-effects model, whichever is proper.

Results: In first-line therapy, gefitinib showed higher odds than chemotherapy (OR = 2.19, 95% CI: 1.20-4.01), but less than other targeted therapies (OR = 0.58, 95% CI: 0.38-0.88). As non-first-line therapy, the overall survival (OS) and progression-free survival (PFS) were similar between gefitinib and controls (HR = 1.00, 95% CI: 0.93-1.08; HR = 0.91, 95% CI: 0.72-1.15), respectively. With the regard to toxicity, the incidences of dry skin, rash and pruritus were higher in gefitinib compared with controls, while gefitinib significantly reduced the incidence of hematologic toxicity.

Conclusion: Gefitinib might be more efficient than chemotherapy, but less efficient than other targeted therapies in ORR, especially in EGFR mutation-positive patients. Gefitinib can decrease the odds of hematologic toxicity compared to controls. Future studies, especially those with EGFR mutation-positive patients, will be needed to confirm our findings.

Keywords: gefitinib, non-small cell lung cancer, meta-analysis, efficacy, toxicity.

Citation styles

APA

Wo, H., He, J., Zhao, Y., Yu, H., Chen, F., Yi, H. (2018). The Efficacy and Toxicity of Gefitinib in Treating Non-small Cell Lung Cancer: A Meta-analysis of 19 Randomized Clinical Trials. Journal of Cancer, 9(8), 1455-1465. https://doi.org/10.7150/jca.23356.

ACS

Wo, H.; He, J.; Zhao, Y.; Yu, H.; Chen, F.; Yi, H. The Efficacy and Toxicity of Gefitinib in Treating Non-small Cell Lung Cancer: A Meta-analysis of 19 Randomized Clinical Trials. J. Cancer 2018, 9 (8), 1455-1465. DOI: 10.7150/jca.23356.

NLM

CSE

Wo H, He J, Zhao Y, Yu H, Chen F, Yi H. 2018. The Efficacy and Toxicity of Gefitinib in Treating Non-small Cell Lung Cancer: A Meta-analysis of 19 Randomized Clinical Trials. J Cancer. 9(8):1455-1465.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.